The association of an IgM-Fc receptor (FcR) with chronic lymphocytic leukemia (CLL) was suggested more than 30 years ago, but its authenticity has never been formally addressed. We exam 
Introduction
Chronic lymphocytic leukemia (CLL) is the most common leukemia of adults in Western countries and accounts for ϳ 30% of all cases of leukemia in the United States. It is a heterogeneous leukemia that is thought to originate from antigen-stimulated B cells that escape from normal cell death mechanisms. 1,2 Survival of CLL patients ranges from a few years to several decades. The most reliable marker thus far for predicting the prognosis of CLL is the mutation status in the immunoglobulin heavy chain variable region (IGHV). Unmutated (UM)-CLL is aggressive and mutated (MT)-CLL is more indolent. [3] [4] [5] Because DNA sequencing is not practical for most clinical laboratories, various cell surface and intracellular proteins have been explored as potential surrogate markers. ZAP-70, a Syk family tyrosine kinase normally expressed in T cells, has proved to be a very good indicator for UM-CLL, but the required intracellular staining is technically challenging and results in diagnostic inconsistency among clinical laboratories. [6] [7] [8] [9] [10] [11] Other markers, including membrane proteins (eg, CD38, Fc receptor-like protein 2) and serum proteins (eg, thymidine kinase, soluble CD23, and ␤2-microglobulin), also have been studied as surrogate prognostic indicators. 3, 4, [12] [13] [14] [15] [16] [17] The association of the IgM Fc receptor (FcR) with CLL has long been suggested based on the ability of CLL cells to form rosettes with IgM-coated erythrocytes. [18] [19] [20] [21] [22] Unfortunately, this early intriguing suggestion was not pursued thereafter, probably because of uncertainties with such a crude detection procedure. During the course of analysis of B-cell activation antigens with the BAC-1 mouse IgM monoclonal antibody (mAb), we serendipitously found an IgM-binding protein of ϳ 60 kDa that was expressed on CLL B cells and activated normal B cells by immunofluorescence and biochemical analyses using various IgM ligands. 23, 24 The gene encoding an authentic FcR has defied identification until our recent discovery of a bona fide FcR cDNA in the B-lineage libraries, including one library derived from CLL B cells. 25 Surprisingly, the corresponding FCMR gene had been already reported as TOSO or Fas apoptosis inhibitory molecule 3 (FAIM3). 26 Notably, the reported inhibition of apoptosis was based on an assay in which apoptosis was induced by ligation of Fas on the Jurkat T-cell line with a mouse IgM mAb (CH11). Our results indicated that FcR per se had no inhibitory activity in Fas-mediated apoptosis and that such inhibition was only achieved when anti-Fas mAb of an IgM but not IgG isotype was used for inducing apoptosis. 25 This incorrect designation has led to the misconception that enhanced FAIM3/TOSO expression by CLL cells may be linked to their resistance to cell death mechanisms. [27] [28] [29] Here, we examined the expression of FcR in CLL patients using receptorspecific mAbs and have shown the enhanced expression of both the membrane-bound and soluble form of the receptor.
Birmingham, AL; all corresponding patients met National Cancer Institute criteria for the diagnosis of CLL. 30 Blood and serum samples also were obtained from adult healthy volunteers. The study was approved by the institutional review boards of University of Alabama at Birmingham and Brookwood Hospital. Written informed consent was obtained from all participants before enrollment in the study in accordance with the Declaration of Helsinki, and all donor samples were made anonymous to maintain health information confidentiality. Serum samples were stored at Ϫ20°C until analysis.
Flow cytometric analysis of cell surface FcR
PBMCs isolated by Ficoll-Hypaque gradient centrifugation were first incubated with an Fc␥ receptor blocking mAb and then with biotin-labeled anti-FcR mAb (HM14 clone; mouse ␥1 isotype) or biotin-labeled irrelevant mAb of ␥1 isotype as a control, along with FITC-labeled anti-CD5 mAb (HISM2 clone; mouse ␥1) and allophycocyanin (APC)-labeled anti-CD19 mAb (HIB19 clone; mouse ␥1). 15, 25 Anti-TOSO mAb (1E4 clone) that was used in a previous publication 27 was purchased from Abnova, biotinylated, and used with the HM14 mAb in a side-by-side comparison of the expression of FcR and TOSO in CLL patients. Phycoerythrin (PE)-labeled streptavidin (SA) was used for detection of biotin mAbs. The stained cells were analyzed using an FACSCalibur flow cytometer (BD Biosciences). Cells stained with the isotype-matched control mAbs labeled with FITC or APC were used to set up the background staining gates. Lymphoid cells with typical forward and side scatter characteristics were gated and examined for their expression of FcR, CD5, and CD19, as described previously. 15 The mean fluorescence intensity (MFI) indices of FcR were determined as the ratio of the MFI of FcR to the MFI of control mAb in the CD5 ؉ /CD19 ؉ CLL B, CD5 Ϫ /CD19 ؉ non-CLL B, and CD5 ؉ /CD19 Ϫ T-cell populations. In some experiments, these three cell populations in CLL patient blood samples were enriched by MoFlo cell sorter (Dako Cytomation) for RNA extraction or for cell culture where sorted cells were cultured at 10 6 /mL in Hybridoma SFM medium (Invitrogen) for 7 days at 37°C under 5% CO 2 . The surface expression of CD38 by CLL B cells and the Rai stage were determined as previously described. 15 
ELISA for soluble FcR
For quantitation of serum levels of soluble FcR (solFcR), a sandwich ELISA was performed. In brief, 96-well plates precoated with mouse anti-human FcR mAb (clone HM6; ␥2b isotype) at a protein concentration of 10 g/mL (and then with BSA [1 mg/mL] to block any free sites) were incubated with 100 L of serial dilutions of serum samples in triplicate. The bound FcR was detected by the addition of biotin-labeled mouse anti-human FcR mAb (HM14) and alkaline phosphatase-labeled SA before addition of the substrate p-nitrophenylphosphate. A biotin-labeled, isotype-matched irrelevant mAb was used as a control. The enzyme reaction was measured by the absorbance at 405 nm with a microplate spectrometer (BioTek Instruments). The serum of a CLL patient that contained high titers of solFcR was used as an internal standard in each plate for all assays. The results were expressed as an arbitrary unit that was determined as follows. At a given optical density value in the linear range, the reciprocal dilutions of the serum samples were divided by the reciprocal dilution of the standard serum, and the lowest measurable value obtained for all the samples was arbitrarily set at 1 unit. When the linear range was not obtained with 10-fold diluted serum samples, the results were scored as undetectable. For determination of the effect of B-cell receptor crosslinkage on production of solFcR, CLL cells were cultured in the presence or absence of a mouse anti-human mAb (SA-DA4.4 clone; IgG1) or an isotype-matched control mAb for 7 days at 37°C under 5% CO 2 before assessment of solFcR in culture supernatants by ELISA. 25 
Western blot analysis of membrane-bound and soluble FcR
For membrane-bound FcR, plasma membrane proteins on PBMCs (10 7 cells) from CLL patients were biotinylated, washed, quenched, and incubated with HM14 anti-FcR or isotype-matched control mAb, before washes and solubilization in 1% nonidet P-40 lysis buffer containing protease inhibitors. The mAb-tagged cell surface proteins were precipitated with rat anti-mouse mAb-coupled beads, dissociated by 1M glycine-HCl buffer, pH 2.85, and resolved on SDS-PAGE under reducing conditions, followed by transfer onto membranes, blot with HRP-SA, and visualization by enhanced chemiluminescence (ECL; GE Healthcare) as described previously. 25 For solFcR, 50 L of sera from 10 different CLL patients or 150 L of culture supernatants from the sorted CLL B and non-CLL B-and T-cell populations were incubated with HM14 anti-FcR or isotypematched control mAb-coupled beads, and the bound materials were dissociated and separated on SDS-10% PAGE under reducing conditions, followed by transfer onto membranes. The membranes were sequentially blotted with biotin-labeled anti-FcR mAbs (HM14 and HM7) and with HRP-SA, before visualization by ECL as described previously. 25 
Mass spectrometric analysis of solFcR
Approximately 20 mL of sera pooled from 3 CLL patients with high titers of solFcR were applied onto 1 mL of Sepharose 4B coupled with F(abЈ) 2 fragments of HM14 anti-FcR mAb (3 mg/mL). After extensive washing, the bound materials were eluted by acid buffer, immediately neutralized, and separated on SDS-10% PAGE, followed by staining with Coomassie Brilliant Blue. The band migrating at ϳ 40 kDa was excised and subjected to mass spectrometric analysis. In brief, the destained gel piece was reduced, alkylated, and then digested with trypsin before extraction of peptides. An aliquot of extracted peptides was applied onto a C 18 reverse-phase cartridge, and the bound peptides were flushed onto a C 18 reverse-phase pulled tip analytical columns. The eluted peptides were passed into a modified MicroIonSpray interface of a 4000 Qtrap mass spectrometer (Applied Biosystems-MDS-Sciex). Possible FcR sequences for monitoring scans were determined using in silico digestion software (MS-Digest, part of the Protein Prospector Version 5.9.2 suite of programs, http://prospector.ucsf.edu/prospector/cgi-bin/msform.cgi?form-msdigest) for possible parent-daughter transitions combination of the splice variant motifs. The multiple reaction monitoring technique with the triple quadrupole detection platform on the 4000 Qtrap mass spectrometer was used as a diagnostic tool for further sample analyses. The first of the 3 quadrupoles selected for the parent mass (parent ion) of the desired analyte. The second quadrupole dissociated the parent ions by collision with an inert gas (N 2 ) into daughter ions (b and y ions). The third quadrupole selected for one of the daughter ions. The parent-daughter ion combination allowed for a highly specific and sensitive diagnostic tool for detection and quantification for specific protein(s) in complex solutions.
RT-PCR
Two micrograms of total RNAs isolated from the sorted cells from CLL patients' blood was converted to first-strand cDNA with an oligo(dT) 18 primer, and the resultant first-strand cDNAs were used as a template DNAs for amplification of FcR transcripts with a set of primers of 5Ј-TCTAGAAGGGACAATGGACT-3Ј (forward) and 5Ј-TCAGGCAGGAA-CATTGATGT-3Ј corresponding to the translation initiation and termination sites of the human FcR cDNA as described previously. 25 Amplification of glyceraldehydes-3-phosphate dehydrogenase (GAPDH) with a set of primers 5Ј-GGTCGGAGTCAACGGATTTGG-3Ј (forward) and 5Ј-CCTC-CGACGCCTGCTTCACCA-3Ј (reverse) was performed as a control. Amplified products were resolved on 1% agarose gel electrophoresis containing ethidium bromide.
IGHV gene sequencing analysis
IGHV mutation status was determined according to established methods as described previously. 15 Sequence data were analyzed in at least 2 databases (IMGT/V-QUEST, JOINSOLVER, National Center for Biotechnology Information IgBLAST), and sequences with a germ line homology of 98% or higher were considered as unmutated and those with a homology Ͻ 98% were considered as mutated.
Statistical analysis
All data comparison was performed by paired Student t test within the same individuals and by pooled Student t test for different groups, and a P value of Ͻ .05 was defined as statistically significant. The Spearman correlation coefficient analysis was used to analyze the relationship between soluble FcR titers and Rai stage in CLL patients.
Results

Enhanced surface expression of FcR in CLL patients
To determine whether the cell surface FcR levels on CLL B cells have any clinical relevance, we conducted a 3-color immunofluorescence analysis of FcR on blood lymphocytes from 40 CLL patients and from 23 healthy donors. The mutation status of IGHV of CLL B-cell receptors in these patients and donors was determined by RT-PCR and nucleotide sequence analyses, and 21 MT-CLL and 19 UM-CLL patients were enrolled in this study. Because FcR is expressed by both B and T lymphocytes, 25 FcR expression was examined for 3 different cell populations in each patient (CD5 ؉ /CD19 ؉ CLL B, CD5 Ϫ /CD19 ؉ non-CLL B and CD5 ؉ /CD19 Ϫ T cells). For healthy donors, who have very few CD5 ؉ /CD19 ؉ B cells, 2 populations (CD5 Ϫ /CD19 ؉ B and CD5 ؉ / CD19 Ϫ T cells) were examined for their FcR expression. As shown in Figure 1A , MT-CLL B cells express significantly higher surface levels of FcR than do UM-CLL B cells (P Ͻ .0001). Moreover, the expression of FcR by both types of CLL B cells was clearly enhanced compared with B cells from healthy donors (P Յ .0001). Within the same individuals, the FcR level of CLL B cells was higher than that of the corresponding non-CLL B cells in both MT-CLL and UM-CLL patients (P Ͻ .0001; Figure 1B) . Remarkably, the FcR levels of both non-CLL B-and T-cell populations in MT-CLL patients and of T cells in UM-CLL patients also were significantly elevated compared with those of normal B and T cells (P Ͻ .003). The surface FcR level of CLL B cells was also negatively correlated with the Rai stage (P ϭ .0317).
The fact that FcR was originally incorrectly identified as TOSO/FAIM3 and reported to inhibit apoptosis has led to some confusion about the expression and role of this molecule in CLL. Therefore, we decided to perform a direct side-by-side comparison of its expression using our FcR-specific HM14 mAb and the previously reported 1E4 TOSO mAb as detection antibodies. Six CLL blood samples (3 MT-CLL and 3 UM-CLL) were examined with essentially the same results for both mAbs ( Figure 1C ). Furthermore, both mAbs were found to recognize a similar or closely distributed epitope on the FcR molecule, because preincubation of FcR ϩ cells with unlabeled HM14 or 1E4 mAb inhibited subsequent reactivity with biotin-labeled 1E4 or HM14 mAb, respectively (supplemental Figure 1 , available on the Blood Web site; see the Supplemental Materials link at the top of the online article). Notably, unlike T and B cells in healthy donors, preincubation in IgM-free media was not necessary for the detection of FcR on CLL cells. In addition, patients with CD38 Ϫ CLL were found to express higher levels of FcR on CLL B cells (P Ͻ .008) and non-CLL B cells (P Ͻ .004), but not on T cells (P ϭ .589) compared with patients with CD38 ϩ CLL.
Collectively, these findings indicate that (1) CLL B cells express higher levels of FcR on their cell surface than B cells of healthy donors as determined by 2 different receptor-specific mAbs; (2) surface FcR levels on CLL B cells negatively correlate with the Rai stage; (3) FcR expression is higher on mutated IGHV or CD38 Ϫ CLL than unmutated IGHV and CD38 ϩ CLL; and (4) enhanced FcR expression is also evident on the non-CLL Band T-cell populations, at least in mutated CLL.
High titers of FcR in the sera from CLL patients
To determine whether CLL patients contain any soluble or extracellular form of FcR in their sera, we performed a sandwich ELISA using one anti-FcR mAb (HM6) for coating plates to capture FcR and another biotin-labeled anti-FcR mAb (HM14) as a developing reagent. Serum samples from 102 different CLL patients (22 MT-CLL, 25 UM-CLL, and 55 untyped) and from 31 healthy donors were analyzed. As shown in Figure 2A , serum titers of FcR are clearly elevated, although there is a wide range, in many CLL patients in comparison with healthy donors (P Ͻ .001). Passage of sera through a 0.22-m filter did not affect the serum titers of FcR, ruling out the possibility of cellular contamination. There was no significant difference in serum FcR titers between MT-CLL and UM-CLL patients. There also was no correlation between serum FcR titers and the Rai stage in CLL (P ϭ .4893). A strong correlation, however, was demonstrated between the serum titers of FcR and the blood lymphocyte counts in CLL patients (r ϭ 0.85; P Ͻ .001).
To determine the relative molecular mass (M r ) of serum FcR in CLL patients, 10 different serum samples with relatively high For personal use only. on September 13, 2017. by guest www.bloodjournal.org From titers of serum FcR were incubated with anti-FcR or control mAb-coupled beads, and the bound materials were analyzed by Western blot analysis with anti-FcR mAbs. As shown in Figure  2C , all of the isolated serum FcR proteins were resolved on SDS-10% PAGE as a single band of ϳ 40 kDa that is distinct in size from the membrane-bound FcR of ϳ 60 kDa. No apparent size heterogeneity was observed with these randomly chosen samples. (A protein of ϳ 30 kDa was occasionally observed in the anti-FcR precipitates, but its molecular identification remains unknown.) These findings thus indicate that many CLL patients' sera contain high levels of an ϳ 40-kDa FcR species that is smaller than the ϳ 60-kDa membrane-bound receptor, and they exclude the possibility that the serum FcR results from the extracellular release of the membrane-bound receptor, for example, by exosome-like vesicles.
Origin and cellular source of the solFcR
In our previous RT-PCR analysis with a set of primers corresponding to the translation initiation and termination sites of the human FcR cDNA, 2 smaller cDNA products of ϳ 1.0 and ϳ 0.9 kb, in addition to the full-length (membrane-bound form) FcR cDNA of ϳ 1.2 kb, were identified in the phorbol myristate acetate (PMA)-activated human pre-B cell line 697. The nucleotide sequence analysis of the 1056-bp cDNA revealed that it was derived from an alternatively spliced FcR transcript that resulted from the direct splicing of exon 4 (stalk 2) to exon 6 (cytoplasmic 1), skipping exon 5 (transmembrane; Figure 3 top panel) . This splicing event results in a reading frame shift in exon 6 and generates a novel 70-amino acid hydrophilic carboxyl-terminal tail, suggesting that this FcR splice variant encodes a soluble form of FcR (gene accession HM480394). (We found that the ϳ 0.9-kb product was nonspecific.)
To determine whether the serum FcR present in CLL patients is generated by this FcR splice variant or by proteolytic cleavage of the membrane-bound receptor, the ϳ 40 kDa serum FcR protein was purified by affinity columns, resolved on SDS-PAGE, and digested with trypsin before mass spectrometric analysis. Four tryptic fragments were found to match the amino-terminal sequences of both the membrane-bound and splice variant forms of FcR, whereas the other 3 tryptic fragments matched only the carboxyl-terminal sequence of the FcR splice variant ( Figure 3A  bottom panel) . Importantly, one of these fragments (QSPLQAG-PPTGR) was found to correspond to the junction formed by splicing exon 4 to exon 6, thereby defining the serum FcR as a soluble form of the receptor encoded by an FcR splice variant ( Figure 3) .
Next, to determine which cells produce the solFcR, the CD5 ؉ /CD19 ؉ CLL B, CD5 Ϫ /CD19 ؉ non-CLL B, and CD5 ؉ / CD19 Ϫ T cells were purified from each mutated and unmutated CLL patient's blood by fluorescence activating cell sorter and were subjected to RT-PCR analysis. The solFcR transcripts of ϳ 1 kb were detectable in CLL B cells and to a lesser extent in non-CLL B cells but undetectable in T cells ( Figure 4A 
Discussion
Using receptor-specific mAbs, we have shown enhanced levels of both the ϳ 60-kDa membrane-bound FcR and the ϳ 40 kDa solFcR in patients with CLL compared with healthy donors. Enhanced surface FcR expression was more evident in IGHV mutated or CD38 Ϫ CLL than IGHV unmutated or CD38 ϩ CLL and was negatively correlated with the Rai stage. Surprisingly, the surface FcR levels in both the CD5 Ϫ non-CLL B-cell and the T-cell populations also were elevated at least in the mutated CLL patients. The serum levels of solFcR in CLL patients strongly correlated with their circulating lymphocyte counts but not with either their IGHV mutation status or Rai stage. The ϳ 40-kDa solFcR was found to be encoded by an alternatively spliced FcR transcript and not by a cleavage of the membrane-bound receptor, and it was produced by both CD5 ؉ CLL B and CD5 Ϫ non-CLL B cells.
Our results thus confirm the constitutive expression of FcR by CLL B cells that was suggested decades ago based on the ability of these cells to form rosettes with IgM-coated erythrocytes [18] [19] [20] [21] [22] and to bind fluorochrome-labeled IgM-ligands. 23, 24 Unlike rosetting assays, the detection of FcR on CLL cells by flow cytometry did not require their preincubation in IgM-free media. Several studies also have demonstrated enhanced expression of FAIM3/TOSO, the former designations of the FCMR gene, in CLL. 6, [27] [28] [29] 31, 32 Two studies found no correlation of TOSO expression levels with prognostic factors, including IGHV mutational status, cytogenetics, and previous treatment. 6, 27 Other studies found that high levels of TOSO expression were correlated with more aggressive leukemia associated with high white blood cell (WBC) counts, advanced Binet stage, unmutated IGHV, and the need for chemotherapy. 28, 29 Gene microarray studies also indicated selective expression of TOSO by naive and memory B cells in tonsils, 33 the findings being consistent with our protein expression data. 25 Our results indicate that surface FcR levels on CLL B cells as determined by both HM14 anti-FcR and 1E4 anti-TOSO mAbs are significantly higher in MT-CLL than UM-CLL and that the discrepancy in the different studies could be because of the detection methods used rather than the patient populations examined in different countries (England, Germany, and the United States). Our assessment was based on immunofluorescence with receptor-specific mAbs, whereas others have mainly relied on RNA expression, either by microarray 6, 27 or RT-PCR analysis. 28, 29 In fact, we have shown previously that the 697 pre-B cell line expressed FcR transcripts constitutively but did not synthesize the cell surface receptor unless it was stimulated with PMA. 24, 25 Although the mechanism for enhanced FcR expression on CLL cells is unclear, it may result from chronic antigenic stimulation as evidenced by (1) reduced levels of membrane IgM, IgD, and CD79/Ig␣/Ig␤ on CLL cells; and (2) reactivity of CLL-derived IgM antibodies with various autoantigens, including the membrane components of apoptotic cells, superantigens, or common antigens. 1, 2, 32 Our previous finding that treatment of normal blood B cells with anti-mAb downmodulates membrane IgM and up-regulates FcR cell surface expression 25 is consistent with the hypothesis that CLL cells are being activated by certain common antigens and that antigendriven stimulation may provide an alternative mode of survival for the leukemic cells.
The inducibility of FcRs by exposure to the corresponding Ig isotopes has been described for various cell types, but such Ig-binding molecules have defied biochemical characterization. For example, IgA-binding capacity of mouse T cells was induced 3) and UM-CLL (lanes 4-6) were enriched from PBMC by cell sorting. Total RNAs were extracted from the sorted cells and converted to first-strand cDNA before PCR amplification using a set of primers corresponding to the FCMR or GAPDH cDNA. An aliquot of the amplified FCMR (top panel) and GAPDH (bottom panel) products was electrophoresed on 1% agarose and stained with ethidium bromide. Lane 7 is a PCR control without a first-strand cDNA template. (B) Western blot analysis of soluble FcR in culture supernatants. The above-sorted cells were cultured at 10 6 cells/mL for 7 days, and the culture supernatants from CLL B (lanes 1 and 2) , non-CLL B (lanes 3 and 4), and T cells (lanes 5 and 6) were analyzed by Western blot as described in "Methods."
by exposure to IgA in vivo and in vitro; 34 however, this binding must be mediated by a non-Fc␣R/CD89 molecule, because mice lack the human Fc␣R/CD89 homolog gene. 35, 36 Similarly, overnight incubation of 697 pre-B cells with IgM led to IgM binding; however, this occurred without the cell surface expression of FcR as determined by receptor-specific mAbs (our unpublished data). 24 In CLL patients, serum Ig levels are typically depressed, but the sera often contain significant amounts of CLL-derived IgM. [37] [38] [39] It will be of interest to determine whether this elevated CLL-derived IgM or the reduced total serum IgM levels contribute to the enhanced expression of surface FcR on CLL cells. Conversely, it also would be interesting to know whether enhanced surface FcR expression, soluble FcR expression, or both contribute to the reduced serum IgM levels in CLL patients.
One of the remarkable findings in our study is the elevated FcR levels on nonleukemic cell populations in MT-CLL patients: CD5 Ϫ non-CLL B cells and T cells. Unlike chronic myelogenous leukemia, which is a stem cell disorder, there is no evidence for CLL being a disorder of a lymphoid committed stem cell. Thus, this enhanced expression could be a secondary effect associated with leukemia. In this regard, there are several precedents describing that nonleukemic cell populations in CLL patients apparently have some abnormal or CLL-induced reactive phenotypes. 40, 41 For example, serum levels of IL-6 and IL-10 (of both viral and human origin) were elevated in CLL patients and correlated with adverse disease features and short survival. Interestingly, the source of these cytokines seemed to be non-B cells for IL-6 and non-CLL B cells for IL-10. 40 Another remarkable example was that T cells in CLL patients were incapable of forming immune synapses with antigen presenting cells because of impaired actin polymerization and that CLL B cells could induce this abnormality in normal allogenic T cells. 41 It is thus conceivable that the surface phenotype and function of nonleukemic cells including non-CLL B cells and T cells from CLL patients are modulated by the bulk of the neoplastic clone. In our previous studies, both circulating B and T cells in healthy donors expressed FcR, but there was a striking difference in their response after antigen receptor ligation or PMA stimulation. FcR expression was up-regulated on B cells but down-modulated on T cells, suggesting differential regulation of FcR expression during Band T-cell activation. 25 Thus, the elevated FcR levels on both non-CLL B and T cells observed in MT-CLL patients are unique, and such enhancement in T cells may be mediated by signals through receptors other than their antigen receptors.
Another remarkable finding is the elevated serum levels of the ϳ 40-kDa solFcR in CLL patients, but not in healthy donors. The solFcR levels are closely correlated with circulating lymphocyte numbers but not with the Rai stage. The ex vivo production of solFcR was not enhanced by anti-mAb treatment. There are precedents for the generation of other soluble receptors by various mechanisms (eg, cleavage of membrane-bound or glycosylphosphate inositol-anchored receptors, alternative splicing, and exosomelike vesicles) in CLL patients. [42] [43] [44] [45] [46] [47] [48] The results from liquid chromatography-tandem mass spectrometry analysis unequivocally defined the ϳ 40-kDa serum FcR as a soluble form of the receptor encoded by an FCMR splice variant. Intriguingly, not only CLL B cells but also non-CLL B cells produced the soluble FcR, and its serum level correlated well with the number of lymphocytes in circulation. The molecular basis for such solFcR production in CLL patients remains unclear as does the clinical effect of such high levels on the immune response of CLL patients. At least 70% of human genes have been shown to express multiple transcripts through alternative splicing of exons or exon segments. 49 In addition, many soluble receptors either derived from neoplastic or non-neoplastic cell populations are elevated in sera from CLL patients, including CD23, CD14, CD44, intercellular adhesion molecule (ICAM)-1 and vascular adhesion molecule (VCAM)-1.
Our study provides new insight into the biology of CLL. The findings may have important clinical applications from 2 perspectives. First, cell surface expression of FcR, which can be easily measured by flow cytometry, may be a valuable new marker for use in clinical laboratories to distinguish MT-CLL from UM-CLL. Second, levels of soluble FcR in serum, which are even easier to measure by ELISA, may correlate with disease progression in CLL. Large patient studies will be required to validate these 2 potential applications.
